Home › NDC Lookup › RxCUI directory › RxCUI 867508

Pazopanib 400 MG Oral Tablet — RxCUI 867508

RxNorm drug concept · Semantic clinical drug
RxCUI 867508 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI867508
Official namePazopanib 400 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known aspazopanib HCl 400 MG Oral Tablet
FDA products mapped1
Package NDCs mapped3
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Pazopanib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Pazopanib targets the signals that allow cancer cells and the blood vessels feeding them to grow. By blocking these signals, it can slow or stop the growth of advanced kidney cance...
  • What exactly is pazopanib treating in my body?
  • Yes, it matters a lot. You should take pazopanib on an empty stomach — at least 1 hour before or 2 hours after eating. Even a light meal can roughly double how much drug gets into...
  • Does it matter if I eat before taking my tablet?
📖 Read our full Pazopanib guide →

🕸️ Concept Web — How Pazopanib 400 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Pazopanib 400 MG Oral Tablet RxCUI 867508

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Pazopanib 714438
  2. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Pazopanib Oral Tablet 867501
    • Pazopanib Oral Product 1161365
    • Pazopanib Pill 1161366
    • Oral Tablet 317541
    • Oral Product 1151131
    • Pill 1151133
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Pazopanib 400 MG 867507

Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Pazopanib 400 MG SCDC · 867507
  • Pazopanib Oral Tablet SCDF · 867501
  • Pazopanib Oral Product SCDG · 1161365
  • Pazopanib Pill SCDG · 1161366

📦 FDA Products & Package NDCs

1 product · 3 package NDCs
3 package NDCs map to RxCUI 867508 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
13668-0735-30 30 TABLET, FILM COATED in 1 BOTTLE (13668-735-30) pazopanib Torrent Pharmaceuticals Limited 2025-09-04
13668-0735-60 60 TABLET, FILM COATED in 1 BOTTLE (13668-735-60) pazopanib Torrent Pharmaceuticals Limited 2025-09-04
13668-0735-90 90 TABLET, FILM COATED in 1 BOTTLE (13668-735-90) pazopanib Torrent Pharmaceuticals Limited 2025-09-04
Observed labelers: Torrent Pharmaceuticals Limited (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.